Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 13/20 | 0.53 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | CBLB | Q13191 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL234917 | 0.91 | MAP3K5 (0.50) | MAP3K5CBLB | |
| SCHEMBL235423 | 0.87 | MAP3K5 (0.48) | MAP3K5CBLBAKT1 | |
| SCHEMBL235196 | 0.87 | MAP3K5 (0.48) | MAP3K5CBLBAKT1 | |
| SCHEMBL232728 | 0.86 | MAP3K5 (0.53) | MAP3K5AKT1 | |
| SCHEMBL943988 | 0.85 | MAP3K5 (0.69) | MAP3K5CCNCCDK8USP30CBLB | |
| SCHEMBL16712435 | 0.83 | MAP3K5 (0.45) | MAP3K5USP30CBLBAKT1 | |
| SCHEMBL230573 | 0.82 | MAP3K5 (0.62) | MAP3K5AKT1 | |
| SCHEMBL232935 | 0.81 | MAP3K5 (0.60) | MAP3K5AKT1 | |
| SCHEMBL233804 | 0.81 | MAP3K5 (0.59) | MAP3K5AKT1 | |
| SCHEMBL232980 | 0.80 | MAP3K5 (0.74) | MAP3K5AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48150-E1 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-2588475-B1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-8927582-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130203819-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-8440665-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2588475-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20120004267-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2012003387-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203819-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | AIFM1, MAP3K1, RIPK3 | MAP3K5 11/4885CCNC 1585/4885CDK8 1004/4885 |
| US-20120004267-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | AIFM1, MAP3K1, RIPK3 | MAP3K5 11/4885CCNC 1585/4885CDK8 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.